MDGL Madrigal Pharmaceuticals Inc

Madrigal Pharmaceuticals (MDGL) recently announced positive two-year Phase 3 data for REZDIFFRA and the appointment of Rita Thakkar as SVP and Chief Accounting Officer. These developments enhance confidence in REZDIFFRA's clinical profile and Madrigal's financial governance, potentially strengthening its market position. The article emphasizes Madrigal's reliance on REZDIFFRA and highlights the wide range of fair value estimates from the Simply Wall St Community.

Voya Investment Management LLC increased its stake in Madrigal Pharmaceuticals (NASDAQ:MDGL) by 16.3% in Q3, bringing its total to 59,437 shares valued at $27.26 million. Despite a Q3 earnings miss and insider share sales worth approximately $41.3 million, institutional investors now own about 98.5% of the company, and analysts generally maintain a "Moderate Buy" rating with a consensus target price of $624.08.

Madrigal Pharmaceuticals (NASDAQ: MDGL) will present at the J.P. Morgan Annual Healthcare Conference on January 12, 2026, marking a significant moment as the company transitions into a commercial-stage biotech. This appearance follows regulatory approvals for its lead therapy, Rezdiffra, the first and only medication approved for MASH with moderate to advanced liver fibrosis. The presentation will offer investors insight into Madrigal's commercialization strategies and clinical expansion plans amidst growing competition in the MASH treatment sector.

Madrigal Pharmaceuticals (NASDAQ:MDGL) has received a consensus "Moderate Buy" rating from fifteen brokers, with an average 1-year price target of $624.08. Despite reporting a significant quarterly EPS miss, the company's stock trades near $603, with institutional ownership at approximately 98.5%. Insider selling totaling roughly $41.3 million occurred last quarter, including trades by the CEO.

Madrigal Pharmaceuticals (NASDAQ:MDGL) stock achieved a new 52-week high, trading at $607.14, driven by analyst upgrades and price target increases from firms like UBS and Piper Sandler. Despite the stock's performance, the company remains unprofitable with negative quarterly EPS and significant insider selling amounting to $41.3 million last quarter. Institutional investors hold a large stake, suggesting continued interest despite the financial losses and insider divestment.

Madrigal Pharmaceuticals Inc. (MDGL) stock has reached an all-time high of $605.86, driven by strong investor confidence and significant revenue growth. The company’s stock has surged 93.77% over the past year and 106.85% in the last six months, with a remarkable 864.21% revenue growth. Analysts have set price targets as high as $900, fueled by the commercial potential of its drug Rezdiffra for MASH, despite the company not yet being profitable.